

SARS-COV-2 LACKING THE ENVELOPE PROTEIN AS AN ATTENUATED VACCINE VIRUS AGAINST COVID-19

View U.S. Patent Application Publication No. W02024/015510 in PDF format.

WARF: P220270W001

Inventors: Yoshihiro Kawaoka, Peter Halfmann, Makoto Kuroda

The Invention

UW-Madison researchers have developed a SARS-CoV-2 live-attenuated vaccine virus based on the original Wuhan genome but lacking the envelope (E) open reading frame. This vaccine virus replicates efficiently in Vero cells that stably express the E protein

Tech Fields

• Therapeutics & Vaccines : Vaccines

For current licensing status, please contact Jennifer Gottwald at jennifer@warf.org or 608-960-9854